Post- American Society of Hematology Annual Meeting (ASH) Survey 2007
December 2007
Description: Survey with key findings.
Study Description:
|
Topic |
Multiple Myeloma |
|
Respondent Type |
Physicians |
|
Specialty |
Oncology/Hematology |
|
Region |
|
|
Methodology |
Online survey, self-administered via a Panel Intelligence website § Self-administered survey § Approximately 30 minutes duration § 54 total respondents § Fielded online from December 12, 2007 to December 18, 2007 |
Objectives:
To determine trends and practices in the treatment of multiple myeloma following data presentations at American Society of Hematology in 2007. Specifically to:
§ Understand multiple myeloma treatment background.
§ Analyze treatment trends for SCT and non-SCT multiple myeloma patients.
§ Assess Revlimid and Velcade data presented at ASH 2007.
§ Evaluate trends in other therapies discussed at ASH 2007.
Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Celgene Corporation |
CELG |
Thalidomide & Revlimid (Lenalidomide) |
|
Genzyme |
GENZ |
Mozobil |
|
Millennium |
MLNM |
Bortezomib (Velcade) |
|
Pharmion Corporation |
PHRM |
Vidaza |
|
Genentech |
DNA |
Rituxan |
|
Cephalon |
CEPH |
Treanda |
|
Inclusion Criteria |
§ US-based board certified hematologists/oncologists § Attended 2007 ASH in § Attended frontline MM session § Treating at least 10 MM patients per month § 2 to 30 years of practice experience § Spend 50%+ of professional time in clinical practice |
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Oncology |